SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
A pill bottle in between two injector pens
Obesity
5 Obesity Readouts to Watch in the Second Half of 2024
Hundreds of companies are currently running clinical trials in the increasingly lucrative obesity space. BioSpace looks at five candidates with data expected before the end of the year.
August 12, 2024
 · 
5 min read
 · 
Heather McKenzie
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Ascendis, Gilead and Regeneron
In the next two weeks, the FDA will hand down its verdicts for three drug applications, including ones for multiple myeloma and hypoparathyroidism therapies.
August 12, 2024
 · 
3 min read
 · 
Tristan Manalac
Hand holding a pill against psychedelic background
Psychedelics
FDA Rejects Lykos’ MDMA-Assisted PTSD Therapy After Negative Adcomm
Clinical trial concerns and a negative advisory committee vote ultimately sunk the treatment.
August 9, 2024
 · 
6 min read
 · 
Kenny Walter
Employees Walking In And Out Of The Door, Some Were Leaving Their Job And Some Were Being Hired At The Same Time. Full Length, Isolated On Solid Color Background. Vector, Illustration, Flat Design, Character.
Layoffs
AN2 Therapeutics Laying Off Half Its Workforce
AN2 is discontinuing a study that evaluated epetraborole for treatment-refractory MAC lung disease and plans to shift focus to its boron chemistry platform.
August 9, 2024
 · 
1 min read
 · 
Angela Gabriel
Merck Research Laboratories headquarters in Silicon Valley
Mergers & acquisitions
Merck Puts Up Potential $1.3B to Acquire Curon’s B Cell Depletion Therapy
Merck is paying $700 million upfront to buy Curon Biopharmaceutical’s bispecific antibody which depletes B cells and is being investigated for non-Hodgkin’s lymphoma and B cell acute lymphocytic leukemia.
August 9, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Sign of U.S. Department of Health & Huma
Policy
J&J’s Stelara More Expensive Under Medicare Part D Than Part B: OIG
With Medicare expenditures on Stelara increasing nearly tenfold, a new report from the HHS Office of Inspector General has found major differences in drug payment amounts under Part B versus Part D.
August 9, 2024
 · 
2 min read
 · 
Tyler Patchen
Novo Nordisk and Eli Lilly buildings
Editorial
Watch Out Novo, Lilly Is Closing the Gap in the Weight-Loss Drug Race
This week, Q2 earnings from Novo Nordisk and Eli Lilly revealed that the competition between the pharma giants’ weight-loss drugs Wegovy and Zepbound is getting closer.
August 9, 2024
 · 
3 min read
 · 
Greg Slabodkin
Photo of a judge's gavel, a balance and a stack of papers
Legal
Federal Judge Tosses Chamber of Commerce Challenge to IRA’s Drug Price Negotiation Program
In the latest setback for the pharma industry and its allies, the United States District Court for the Southern District of Ohio dismissed a U.S. Chamber of Commerce lawsuit on the grounds of improper venue.
August 9, 2024
 · 
2 min read
 · 
Tristan Manalac
Gilead's headquarters in Silicon Valley
Earnings
Gilead Beats Q2 Wall Street Estimates on Strong HIV, Cancer, Liver Disease Sales
Gilead Sciences’ liver disease portfolio delivered surprisingly robust performance in the second quarter, jumping 17% as the company awaits next week’s potential FDA approval of seladelpar in primary biliary cholangitis.
August 9, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS